Download PDF
Zeitschrift für Orthomolekulare Medizin 2016; 2(02): 6-14
DOI: 10.1055/s-0042-106429
Wissen
Karl F. Haug Verlag in Georg Thieme Verlag KG Stuttgart · New York

ω-3-Fettsäuren und Hirnfunktion

Clemens von Schacky
Further Information

Publication History

Publication Date:
26 July 2016 (online)

    Permissions and Reprints

Zusammenfassung

Die ω-3-Fettsäuren EPA und DHA sind von entscheidender Bedeutung für die optimale Hirnfunktion. Zur Beurteilung der Versorgung mit diesen Fettsäuren sind Biomarker wie der HS-Omega-3 Index® zu bevorzugen. Niedrige Spiegel von EPA und DHA sind u. a. Prädiktoren für eingeschränkte komplexe Hirnleistungen und psychiatrische Erkrankungen wie ADHS und Depression. Anzustreben ist ein HS-Omega-3 Index von 8-11 %.

Schlüsselwörter

ω-3-Fettsäuren - EPA - DHA - Hirnfunktion - Biomarker - HS-Omega-3 Index® - Hirnaufbau - psychiatrische Erkrankungen
 

  • Literatur

  • 1 Setiawan E, Wilson AA, Mizrahi R et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015; 72: 268-275
    CrossrefGoogle Scholar
  • 2 Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochem Biophys Acta 2015; 1851: 469-484
    Google Scholar
  • 3 Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol 2015; 27: 200-215
    CrossrefGoogle Scholar
  • 4 von Schacky C. Hirnstruktur und Hirnfunktion: Rolle der Omega-3-Fettsäuren. Z Orthomol Med 2014; 1: 20-24
    Google Scholar
  • 5 Archer E, Hand GA, Blair SN. Validity of U.S. nutritional surveillance: National Health and Nutrition Examination Survey caloric energy intake data, 1971-2010. PLoS One 2013; 8: e76632
    CrossrefGoogle Scholar
  • 6 Köhler A, Bittner D, Löw A, von Schacky C. Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index. Br J Nutr 2010; 104: 729-736
    CrossrefGoogle Scholar
  • 7 Harris WS, von Sc, Park Y. Standardizing Methods for Assessing Omega-3 Fatty Acid Biostatus. In: McNamara RK, ed. The Omega-3 Fatty Acid Deficiency Syndrome. Hauppauge NY: Nova Science Publishers; 2013: 385-398
    Google Scholar
  • 8 Harris WS, Sands SA, Windsor SL et al. Omega-3 Fatty Acid Levels in Transplanted Human Hearts: Effect of Supplementation and Comparison with Erythrocytes. Circulation 2004; 110: 1645-1649
    CrossrefGoogle Scholar
  • 9 Harris WS, Thomas RM. Biological variability of blood omega-3 biomarkers. Clin Biochem 2010; 43: 338-340
    CrossrefGoogle Scholar
  • 10 Arnold C, Markovic M, Blossey K. Arachidonic acid-metabolizing cytochrome P-450 enzymes are targets of omega-3 fatty acids. J Biol Chem 2010; 285: 32720-32733
    CrossrefGoogle Scholar
  • 11 Harris WS, von Schacky C. The Omega-3 Index: A New Risk Factor for Death from CHD?. Prev Med 2004; 39: 212-220
    CrossrefGoogle Scholar
  • 12 von Schacky C. Omega-3 Fatty Acids in Cardiovascular Disease - an Uphill Battle. Prostaglandins Leukot Ess Fatty Acids 2015; 92: 41-47
    Google Scholar
  • 13 Amin AA, Menon RA, Reid KJ et al. Acute Coronary Syndrome Patients With Depression Have Low Blood Cell Membrane Omega-3 Fatty Acid Levels. Psychosom Med 2008; 70: 856-862
    CrossrefGoogle Scholar
  • 14 Ali S, Garg SK, Cohen BE et al. Association between omega-3 fatty acids and depressive symptoms among patients with established coronary artery disease: Data from the Heart and Soul Study. Psychother Psychosom 2009; 78: 125-127
    CrossrefGoogle Scholar
  • 15 Carney RM, Freedland KE, Rubin EH et al. Omega-3 Augmentation of Sertaline in Treatment of Depression in Patients with Coronary Heart Disease. JAMA 2009; 302: 1651-1653
    CrossrefGoogle Scholar
  • 16 Baghai TC, Varallo-Bedarida G, Born C. Major depression is associated with cardiovascular risk factors and low Omega-3 Index. J Clin Psychiat 2011; 72: 1242-1247
    CrossrefGoogle Scholar
  • 17 Park Y, Kim M, Baek D, Kim SH. Erythrocyte n-3 polyunsaturated fatty acids and seafood intake decrease risk of depression: Case-control study in Korea. Ann Nutr Metab 2012; 61: 25-31
    CrossrefGoogle Scholar
  • 18 Baek D, Park Y. Association between erythrocyte n-3 polyunsaturated fatty acids and biomarkers of inflammation and oxidative stress in patients with and without depression. Prostaglandins Leukot Essent Fatty Acids 2013; 89: 291-296
    CrossrefGoogle Scholar
  • 19 Persons JE, Robinson JG, Coryell WH et al. Omega-3 fatty acid biomarkers and subsequent depressive symptoms. Int J Geriatr Psychiatry 2014; 29: 747-757
    CrossrefGoogle Scholar
  • 20 Hibbeln JR, Gow RV. The potential for military diets to reduce depression, suicide, and impulsive aggression: a review of current evidence for omega-3 and omega-6 fatty acids. Mil Med 2014; 117-128
    Google Scholar
  • 21 Johnston DT, Deuster PA, Harris WS et al. Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed U.S. servicemembers. Nutr Neurosci 2013; 16: 30-38
    CrossrefGoogle Scholar
  • 22 Tan ZS, Harris WS, Beiser AS et al. Red Blood Cell Omega-3 Fatty Acid Levels and Markers of Accelerated Brain Aging. Neurology 2012; 78: 658-664
    CrossrefGoogle Scholar
  • 23 Ammann EM, Pottala JV, Harris WS. Omega-3 fatty acids and domain-specific cognitive aging: Secondary analyses of data from WHISCA. Neurology 2013; 81: 1484-1191
    CrossrefGoogle Scholar
  • 24 Pottala JV, Yaffe K, Robinson J et al. Higher RBC EPA+DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study. Neurology 2014; 82: 435-442
    CrossrefGoogle Scholar
  • 25 Rice HB, Bernasconi A, Maki KC et al. Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014. Prostaglandins Leukot Essent Fatty Acids 2016; 107: 30-42
    CrossrefGoogle Scholar
  • 26 Muhlhausler BS, Gibson RA, Yelland LN, Makrides M. Heterogeneity in cord blood DHA concentration: towards an explanation. Prostaglandins Leukot Essent Fatty Acids 2014; 91: 135-140
    CrossrefGoogle Scholar
  • 27 Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63: 1402-1408
    CrossrefGoogle Scholar
  • 28 Chiu CC, Su KP, Cheng TC et al. The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1538-1544
    CrossrefGoogle Scholar
  • 29 Johnson EJ, McDonald K, Caldarella SM et al. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci 2008; 11: 75-83
    CrossrefGoogle Scholar
  • 30 Yurko-Mauro K, McCarthy D, Rom D et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010; 6: 456-464
    CrossrefGoogle Scholar
  • 31 Rondanelli M, Opizzi A, Faliva M et al. Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment. Nutr Neurosci 2012; 15: 46-54
    CrossrefGoogle Scholar
  • 32 Scheltens P, Twisk JW, Blesa R et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis 2012; 31: 225-236
    Google Scholar
  • 33 Sinn N, Milte cm, Street SJ et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 2012; 107: 1682-1693
    CrossrefGoogle Scholar
  • 34 Lee LK, Shahar S, Chin AV, Yusoff NA. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology 2013; 225: 605-612
    CrossrefGoogle Scholar
  • 35 Stonehouse W, Conlon CA, Podd J et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am J Clin Nutr 2013; 97: 1134-1143
    CrossrefGoogle Scholar
  • 36 de Wa, Stam CJ, Lansbergen MM et al. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer‘s disease: a randomised controlled study. PLoS One 2014; 9: e86558
    CrossrefGoogle Scholar
  • 37 Witte AV, Kerti L, Hermannstädter HM et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex 2014; 24: 3059-3068
    CrossrefGoogle Scholar
  • 38 Pardini M, Serrati C, Guida S et al. Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. Neurodegener Dis 2015; 15: 58-62
    CrossrefGoogle Scholar
  • 39 Strike SC, Carlisle A, Gibson EL, Dyall SC. A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study. J Gerontol A Biol Sci Med Sci 2016; 71: 236-242
    CrossrefGoogle Scholar
  • 40 Kotani S, Sakaguchi E, Warashina S. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006; 56: 159-164
    CrossrefPubMedGoogle Scholar
  • 41 Rogers PJ, Appleton KM, Kessler D et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008; 99: 421-431
    Google Scholar
  • 42 van de, Geleijnse JM, Kok FJ et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008; 71: 430-438
    CrossrefGoogle Scholar
  • 43 van de, Geleijnse JM, Kok FJ et al. Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2008; 88: 706-713
    Google Scholar
  • 44 Dangour AD, Allen E, Elbourne D et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 2010; 91: 1725-1732
    CrossrefGoogle Scholar
  • 45 Andreeva VA, Kesse-Guyot E, Barberger-Gateau P et al. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. Am J Clin Nutr 2011; 94: 278-286
    CrossrefGoogle Scholar
  • 46 Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimers Dement 2012; 8: 278-287
    CrossrefGoogle Scholar
  • 47 Jackson PA, Deary ME, Reay JL et al. No effect of 12 weeks’ supplementation with 1 g DHA-rich or EPA-rich fish oil on cognitive function or mood in healthy young adults aged 18-35 years. Br J Nutr 2012; 107: 1232-1243
    CrossrefGoogle Scholar
  • 48 Karr JE, Grindstaff TR, Alexander JE. Omega-3 polyunsaturated fatty acids and cognition in a college-aged population. Exp Clin Psychopharmacol 2012; 20: 236-242
    CrossrefGoogle Scholar
  • 49 Nilsson A, Radeborg K, Salo I, Björck I. Effects of supplementation with n-3 polyunsaturated fatty acids on cognitive performance and cardiometabolic risk markers in healthy 51 to 72 years old subjects: a randomized controlled cross-over study. Nutr J 2012; 11: 99
    CrossrefGoogle Scholar
  • 50 Sinn N, Milte cm, Street SJ et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 2012; 107: 1682-1693
    CrossrefGoogle Scholar
  • 51 Stough C, Downey L, Silber B. The effects of 90-day supplementation with the omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. Neurobiol Aging 2012; Apr; 33 (4): 824.e1–3
    Google Scholar
  • 52 Benton D, Donohoe RT, Clayton DE, Long SJ. Supplementation with DHA and the psychological functioning of young adults. Br J Nutr 2013; 109: 155-161
    CrossrefGoogle Scholar
  • 53 Cukierman-Yaffe T, Bosch J, Diaz R et al. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes Endocrinol 2014; 2: 562-572
    Google Scholar
  • 54 Jaremka LM, Derry HM, Bornstein R et al. Omega-3 supplementation and loneliness-related memory problems: secondary analyses of a randomized controlled trial. Psychosom Med 2014; 76: 650-658
    CrossrefGoogle Scholar
  • 55 Chew EY, Clemons TE, Agrón E et al. Age-Related Eye Disease Study 2 (AREDS2) Research Group. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. JAMA 2015; 314: 791-801
    CrossrefGoogle Scholar
  • 56 Jackson N, Atar D, Borentain M et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. Eur Heart J 2016; 37: 747-754
    CrossrefGoogle Scholar
  • 57 Koletzko B, Lien E, Agostoni C et al. The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med 2008; 36: 5-14
    CrossrefGoogle Scholar
  • 58 McNamara RK, Vannest JJ, Valentine CJ. Role of perinatal long-chain omega-3 fatty acids in cortical circuit maturation: Mechanisms and implications for psychopathology. World J Psychiatry 2015; 5: 15-34
    Google Scholar
  • 59 Stonehouse W. Does consumption of LC omega-3 PUFA enhance cognitive performance in healthy school-aged children and throughout adulthood? Evidence from clinical trials. Nutrients 2014; 6: 2730-2758
    CrossrefGoogle Scholar
  • 60 Chouinard-Watkins R, Plourde M. Fatty acid metabolism in carriers of apolipoprotein E epsilon 4 allele: is it contributing to higher risk of cognitive decline and coronary heart disease?. Nutrients 2014; 6: 4452-4471
    CrossrefGoogle Scholar
  • 61 Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev 2014; 34: 496-505
    CrossrefGoogle Scholar
  • 62 Widenhorn-Müller K, Schwanda S, Scholz E et al. Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): A randomized placebo-controlled intervention trial. Prostaglandins Leukot Essent Fatty Acids 2014; 91: 49-60
    CrossrefGoogle Scholar
  • 63 Montgomery P, Burton JR, Sewell RP et al. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: a cross-sectional analysis from the DOLAB study. PLoS One 2013; 8: e66697
    CrossrefGoogle Scholar
  • 64 Bos DJ, Oranje B, Veerhoek ES et al. Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder. Neuropsychopharmacology 2015; 40: 2298-2306
    CrossrefGoogle Scholar
  • 65 Wu Q, Zhou T, Ma L et al. Protective effects of dietary supplementation with natural ω-3 polyunsaturated fatty acids on the visual acuity of school-age children with lower IQ or attention-deficit hyperactivity disorder. Nutrition 2015; 31: 935-940
    CrossrefGoogle Scholar
  • 66 Dashti N, Hekmat H, Soltani HR et al. Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin®) in treating children with attention deficit hyperactivity disorder. Iran J Psychiatry Behav Sci 2014; 8: 7-11
    Google Scholar
  • 67 Raine A, Portnoy J, Liu J. Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years: a randomized, double-blind, placebo-controlled, stratified, parallel-group trial. J Child Psychol Psychiatry 2015; 56: 509-520
    CrossrefGoogle Scholar
  • 68 Pottala JV, Churchill SW, Talley JA et al. Red Blood Cell Fatty Acids are Associated with Depression in a Case-Control Study of Adolescents. Prostaglandins Leukot Essent Fatty Acids 2012; 86: 161-165
    CrossrefGoogle Scholar
  • 69 Sublette ME, Galfalvy HC, Hibbeln JR et al. Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder. Int J Neuropsychopharmacol 2014; 17: 383-391
    CrossrefGoogle Scholar
  • 70 Voggt A, Berger M, Obermeier M et al. Heart rate variability and omega-3 index in euthymic patients with bipolar disorders. Eur Psy 2015; 30: 228-232
    Google Scholar
  • 71 Grosso G, Pajak Ma, Castellano S et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014; 9: e96905
    CrossrefPubMedGoogle Scholar
  • 72 McNamara RK, Jandacek R, Tso P. Lower docosahexaenoic acid concentrations in the postmortem prefrontal cortex of adult depressed suicide victims compared with controls without cardiovascular disease. J Psychiatr Res 2013; 47: 1187-1191
    CrossrefGoogle Scholar
  • 73 Hallahan B, Hibbeln JR, Davis JM, Garland MR. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry 2007; 190: 118-122
    CrossrefGoogle Scholar
  • 74 Mischoulon D, Freeman MP. Omega-3 fatty acids in psychiatry. Psychiatr Clin North Am 2013; 36: 15-23
    CrossrefGoogle Scholar
  • 75 Pawełczyk T, Grancow M, Kotlicka-Antczak M et al. Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale design, and methods. BMC Psychiatry 2015; 15: 97
    CrossrefGoogle Scholar
  • 76 Messamore E, McNamara RK. Detection and treatment of omega-3 fatty acid deficiency in psychiatric practice: Rationale and implementation. Lipids Health Dis 2016; 15: 25
    CrossrefGoogle Scholar
  • 77 Jiao J, Li Q, Chu J. Effect of n-3 PUFA supplementation on cognitive function throughout the life span from infancy to old age: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014; 100: 1422-1436
    CrossrefGoogle Scholar
  • 78 Gould JF, Makrides Co, Smithers LG. Randomized controlled trial of maternal omega-3 long-chain PUFA supplementation during pregnancy and early childhood development of attention, working memory, and inhibitory control. Am J Clin Nutr 2014; 99: 851-859
    CrossrefGoogle Scholar
  • 79 Kuratko CN, Barrett EC, Nelson EB, Salem NJr.. The relationship of docosahexaenoic acid (DHA) with learning and behavior in healthy children: a review. Nutrients 2013; 5: 2777-2810
    CrossrefGoogle Scholar
  • 80 Gow RV, Hibbeln JR. Omega-3 fatty acid and nutrient deficits in adverse neurodevelopment and childhood behaviors. Child Adolesc Psychiatr Clin N Am 2014; 23: 555-590
    CrossrefPubMedGoogle Scholar
  • 81 Montgomery P, Burton JR, Sewell RP. Fatty acids and sleep in UK children: subjective and pilot objective sleep results from the DOLAB study - a randomized controlled trial. J Sleep Res 2014; 23: 364-388
    CrossrefGoogle Scholar
  • 82 Johnston DT, Deuster PA, Harris WS. Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed U.S. Servicemembers. Nutr Neurosci 2013; 16: 30-38
    CrossrefGoogle Scholar
  • 83 Bauer I, Hughes M, Rowsell R. Omega-3 supplementation improves cognition and modifies brain activation in young adults. Hum Psychopharmacol 2014; 29: 133-144
    CrossrefGoogle Scholar
  • 84 Giles GE, Mahoney CR, Urry HL et al. Omega-3 fatty acids and stress-induced changes to mood and cognition in healthy individuals. Pharmacol Biochem Behav 2015; 132: 10-19
    CrossrefGoogle Scholar
  • 85 Park Y, Park S, Yi H et al. Low level of n-3 polyunsaturated fatty acids in erythrocytes is a risk factor for both acute ischemic and hemorrhagic stroke in Koreans. Nutr Res 2009; 29: 825-830
    CrossrefGoogle Scholar
  • 86 Yamagishi K, Folsom AR, Steffen LM. ARIC Study Investigators. Plasma fatty acid composition and incident ischemic stroke in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Cerebrovasc Dis 2013; 36: 38-46
    CrossrefGoogle Scholar
  • 87 Raji CA, Erickson KI, Lopez OL et al. Regular fish consumption and age-related brain gray matter loss. Am J Prev Med 2014; 47: 444-451
    CrossrefGoogle Scholar
  • 88 Külzow N, Witte AV, Kerti L et al. Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults. J Alzheimer Dis 2016; 713-725
    Google Scholar
  • 89 Jernerén F, Elshorbagy AK, Oulhaj A et al. Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. Am J Clin Nutr 2015; 102: 215-221
    CrossrefGoogle Scholar
  • 90 Wu S, Ding Y, Wu F et al. Omega-3 fatty acids intake and risks of dementia and Alzheimer’s disease: a meta-analysis. Neurosci Biobehav Rev 2015; 48: 1-9
    CrossrefGoogle Scholar
  • 91 Daiello LA, Gongvatana A, Dunsiger S et al. Association of fish oil supplement use with preservation of brain volume and cognitive function. Alzheimers Dement 2015; 11: 226-235
    CrossrefGoogle Scholar
  • 92 Quinn JF, Raman R, Thomas RG et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010; 304: 1903-1911
    CrossrefGoogle Scholar
  • 93 Zhang W, Wang H, Zhang H et al. Dietary supplementation with omega-3 polyunsaturated fatty acids robustly promotes neurovascular restorative dynamics and improves neurological functions after stroke. Exp Neurol 2015; 272: 170-180
    CrossrefGoogle Scholar
  • 94 Barrett EC, McBurney MI, Ciappio ED. ω-3 fatty acid supplementation as a potential therapeutic aid for the recovery from mild traumatic brain injury/concussion. Adv Nutr 2014; 5: 268-277
    CrossrefGoogle Scholar
  • 95 Jelinek GA, Hadgkiss EJ, Weiland TJ et al. Association of fish consumption and Ω-3 supplementation with quality of life, disability and disease activity in an international cohort of people with multiple sclerosis. Int J Neurosci 2013; 123: 792-800
    CrossrefGoogle Scholar
  • 96 Torkildsen O, Wergeland S, Bakke S et al. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 2012; 69: 1044-1051
    Google Scholar
  • 97 Fitzgerald KC, O‘Reilly J, Falcone GJ et al. Dietary ω-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol 2014; 71: 1102-1110
    CrossrefGoogle Scholar
  • 98 Wills AM, Hubbard J, Macklin EA et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014; 383: 2065-2072
    CrossrefGoogle Scholar
  • 99 Zaalberg A, Wielders J, Bulten E et al. Relationships of diet-related blood parameters and blood lead levels with psychopathology and aggression in forensic psychiatric inpatients. 2015, Mar 31 Crim Behav Ment Health 2015; Mar 31 DOI: 10.1002/cbm.1954. [Epub ahead of print].
    Google Scholar
  • 100 Meyer BJ, Byrne MK, Collier C et al. Baseline omega-3 index correlates with aggressive and attention deficit disorder behaviours in adult prisoners. PLoS One 2015; 10: e0120220
    CrossrefGoogle Scholar
  • 101 Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Res 2015; 17: 62
    CrossrefGoogle Scholar
  • 102 von Schacky C. Der HS-Omega 3 Index®: klinische Wertigkeit standardisierter Fettsäureanalytik. J Lab Med 2014; 38: 167-178
    Google Scholar